Targovax Company

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

Total Funding: 30331820
Headquarters: Oslo, Oslo, Norway
Funding Status: IPO
Estimated Revenue: $1M to $10M
Last Funding Type: Grant
Last Funding Date: 2022-01-12
Investors Number: 5
Founded Date: 2010-01-01
Industry: Peptides and Proteins